TABLE 1.
Antimicrobial susceptibilities of clinical isolates and transformants
| Antimicrobial agent | MIC (μg/ml)
|
||||
|---|---|---|---|---|---|
| C. freundii 13692 | E. coli TF/13692 | K. oxytoca 15002 | E. coli TF/15002 | E. colia | |
| Ertapenem | >16 | >16 | >16 | >16 | ≤0.5 |
| Imipenem | 16 | >16 | 8 | 32 | ≤1 |
| Meropenem | 16 | >16 | >16 | >16 | ≤0.25 |
| Amikacin | 2 | 2 | ≤1 | 2 | 2 |
| Amoxicillin-clavulanate | >32/16 | >32/16 | >32/16 | >32/16 | 4/2 |
| Ampicillin | >64 | >32 | >64 | >32 | 4 |
| Aztreonam | >64 | >64 | >64 | >64 | ≤1 |
| Cefepime | >32 | >32 | >32 | >32 | ≤0.5 |
| Cefotaxime | >256 | 256 | 256 | 256 | 2 |
| Cefotaxime-clavulanate | 128/4 | 32/4 | 2/4 | 32/4 | |
| Cefoxitin | >32 | >32 | 32 | >32 | 4 |
| Cefpodoxime | >16 | >16 | >16 | >16 | 1 |
| Ceftazidime | >256 | 64 | 32 | 128 | ≤4 |
| Ceftazidime-clavulanate | 256/4 | 64/4 | 16/4 | 64/4 | ≤2/4 |
| Ceftriaxone | >64 | >64 | >64 | >64 | ≤1 |
| Chloramphenicol | >16 | ≤2 | 8 | ≤2 | ≤2 |
| Ciprofloxacin | >8 | ≤0.25 | 8 | ≤0.12 | ≤0.12 |
| Colistin | 1 | 0.5 | 1 | 2 | 1 |
| Gentamicin | 16 | 0.5 | ≤0.25 | 0.5 | 1 |
| Levofloxacin | >8 | ≤0.25 | 8 | ≤0.25 | ≤0.25 |
| Piperacillin-tazobactam | >128/4 | >128/4 | >64/4 | >128/4 | 2/4 |
| Polymyxin B | 1 | 0.5 | 1 | ≤0.5 | 1 |
| Tigecycline | 1 | 0.12 | 1 | 0.12 | 0.12 |
| Tobramycin | 16 | 0.5 | ≤0.25 | 0.5 | 0.5 |
| Trimethoprim-sulfamethoxazole | >8/152 | ≤0.25/4.75 | ≤0.25/4.75 | ≤0.25/4.75 | ≤0.25/4.75 |
a
E. coli EP-Max 10B competent cells were used for transformation by electroporation.